CoChat

Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment

Open access
Nowicki, M., Rychlik, I., Haller, H., Warren, M. L., Suchower, L., Gause‐Nilsson, I., for the D1680C00007 Investigators · 2011 · Diabetes, Obesity and Metabolism
Cited by 131

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Aim: To evaluate the efficacy and safety of saxagliptin vs. placebo in patients with type 2 diabetes mellitus (T2DM) and renal impairment. Methods: In this multicentre, randomized, parallel‐group, double‐blind, placebo‐controlled study, patients with glycated haemoglobin (HbA1c) 7–11% and creatinine clearance <50 ml/min were stratified by baseline renal impairment (moderate, severe or end‐stage on haemodialysis), and randomized (1 : 1) to saxagliptin 2.5 mg once daily or placebo for 12 weeks. Oral antihyperglycaemic drugs and insulin therapy present at enrolment were continued throughout the study. The absolute change in HbA1c from baseline to week 12 (primary efficacy end‐point) was analysed using an analysis of covariance model with last observation carried forward methodology. Results: A total of 170 patients were randomized and treated. The adjusted mean decrease from baseline to week 12 in HbA1c was statistically significantly greater in the saxagliptin group than in the placebo group; the difference between treatments was −0.42% (95% confidence interval: −0.71 to −0.12%, p = 0.007). Adjusted mean HbA1c decreases from baseline to week 12 were numerically greater with saxagliptin than with placebo in the subgroups of patients with moderate (−0.64 vs. −0.05%) and severe (−0.95 vs. −0.50%) renal impairment. HbA1c reductions were similar between saxagliptin and placebo in the subgroup with end‐stage renal disease on haemodialysis (−0.84 vs. −0.87%). Saxagliptin was generally well tolerated; incidences of adverse events and hypoglycaemic events were similar to placebo. Conclusions: Saxagliptin 2.5 mg once daily is a well‐tolerated treatment option for patients with inadequately controlled T2DM and renal impairment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2011.01382.x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 131

Metadata

Authors
Nowicki, M., Rychlik, I., Haller, H., Warren, M. L., Suchower, L., Gause‐Nilsson, I., & for the D1680C00007 Investigators
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2011-04-20
Volume
13
Issue
6
Pages
523-532
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2045321591
Cited by
131
References
1
FWCI
17.89
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment. https://app.cochat.ai/papers/10.1111/j.1463-1326.2011.01382.x
The paper
Nowicki, M., Rychlik, I., Haller, H., Warren, M. L., Suchower, L., Gause‐Nilsson, I., & for the D1680C00007 Investigators. (2011). Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2011.01382.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.